The Immune Response Corporation (OTCBB:IMNR) announced today that it will restate its first quarter financial statements to add approximately $100 million of phantom income, which has nothing to do with the Company’s operations. Also, there will be additional phantom income of similar magnitude in the second quarter of 2006. These items do not reflect any change in the Company’s results of operations or cash position, but are required under a recent clarification of Generally Accepted Accounting Principles.
